TAS1553   Click here for help

GtoPdb Ligand ID: 12113

Synonyms: TAS-1553
Compound class: Synthetic organic
Comment: TAS1553 is a small-molecule inhibitor of the interaction between ribonucleotide reductase R1 and R2 subunits [1]. It binds to the R1 subunit. As a rate-limiting enzyme for dNTP production, ribonucleotide reductase is a molecular target for cancer therapeutics, as its inhibition blocks DNA synthesis and inhibits proliferation of tumour cells. TAS1553 is orally bioavailable.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 156.53
Molecular weight 482.08
XLogP 3.74
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Clc1ccc(c(c1)C(=O)N)S(=O)(=O)N[C@@H]([C@@H](c1c(F)ccc(c1C)C)C)c1n[nH]c(=O)o1
Isomeric SMILES C[C@@H]([C@H](NS(=O)(=O)c1ccc(Cl)cc1C(=O)N)c1n[nH]c(=O)o1)c1c(C)c(C)ccc1F
InChI InChI=1S/C20H20ClFN4O5S/c1-9-4-6-14(22)16(10(9)2)11(3)17(19-24-25-20(28)31-19)26-32(29,30)15-7-5-12(21)8-13(15)18(23)27/h4-8,11,17,26H,1-3H3,(H2,23,27)(H,25,28)/t11-,17+/m1/s1
InChI Key DUYRWEBTZNUILI-DIFFPNOSSA-N
No information available.
Summary of Clinical Use Click here for help
TAS1553 has entered early satge clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04637009 A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms Phase 1 Interventional Astex Pharmaceuticals, Inc.